{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:16:34Z","timestamp":1776824194298,"version":"3.51.2"},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019271","name":"Kyorin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["LUTS"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the safety and effectiveness of vibegron, a highly selective \u03b2<jats:sub>3<\/jats:sub>\u2010adrenoceptor agonist, in Japanese patients with overactive bladder (OAB) in a real\u2010world clinical setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This prospective survey was conducted from August 2019 to July 2023 using a central registration method. Patients newly treated with vibegron for OAB were followed for 12\u2009weeks, and those who continued treatment were observed for up to 52\u2009weeks. Adverse drug reactions (ADRs) and the overall improvement level were assessed, and overactive bladder symptom score (OABSS) and International Prostate Symptom Score\u2010Quality of Life (IPSS QOL) score were collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 1848 patients in the safety analysis set, 154 ADRs were reported in 141 patients (7.63%). Common ADRs were increased residual urine volume (1.30%), constipation (1.14%), dysuria and urinary retention (0.97% each), cystitis (0.65%), and dry mouth (0.32%). The incidence of urinary retention\u2010related adverse events (AEs) was higher in male patients, patients \u2265\u200965\u2009years old, and patients with benign prostatic hyperplasia. The effectiveness rate was 88.8% among the 1561 patients in the effectiveness analysis set. Significant improvement in both OABSS and IPSS QOL scores was observed at all observation periods. The rate of achieving the minimal clinically important change in OABSS total score at the final evaluation was 75.35%. OABSS scores were also significantly reduced in all subgroup analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This survey found no major concerns regarding the safety and effectiveness of vibegron in Japanese OAB patients, except for urinary retention\u2010related AEs. Vibegron is considered to represent a useful drug for treating OAB symptoms in a real\u2010world clinical setting.<\/jats:p><\/jats:sec>","DOI":"10.1111\/luts.12535","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T09:00:14Z","timestamp":1730797214000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and Effectiveness of Vibegron in Japanese Patients With Overactive Bladder: A Japanese Postmarketing Survey"],"prefix":"10.1111","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5347-1365","authenticated-orcid":false,"given":"Shoko","family":"Yoshimura","sequence":"first","affiliation":[{"name":"Pharmacovigilance Department Kyorin Pharmaceutical Co. Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Yagi","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Department Kyorin Pharmaceutical Co. Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Abe","sequence":"additional","affiliation":[{"name":"Pharmacovigilance &amp; Post\u2010Marketing Surveillance Kissei Pharmaceutical Co. Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Department Kyorin Pharmaceutical Co. Ltd.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02243-4"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.10013.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2012.04.004"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S102441"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09993.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05835.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00622-7"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.08.017"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02626.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61994-3"},{"issue":"3","key":"e_1_2_9_12_1","first-page":"1367","article-title":"Evidence for Beta3\u2010Adrenoceptor Subtypes in Relaxation of the Human Urinary Bladder Detrusor: Analysis by Molecular Biological and Pharmacological Methods","volume":"288","author":"Takeda M.","year":"1999","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702358"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01372"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.237313"},{"key":"e_1_2_9_16_1","article-title":"Long\u2010Term Efficacy and Safety of Vibegron Versus Mirabegron and Anticholinergics for Overactive Bladder: A Systematic Review and Network Meta\u2010Analysis","volume":"11","author":"Kennelly M.","year":"2022","journal-title":"Drugs in Context"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.12.022"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000807"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.5213\/inj.2346022.011"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15020"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13877"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.24732"},{"key":"e_1_2_9_23_1","unstructured":"Pharmaceutical Administration and Regulations in Japan \u201cJapanese Pharmaceutical Manufacturers Association \u201d2020 https:\/\/www.jpma.or.jp\/english."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/20420986211065215"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2328w"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.06.020"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13422"},{"issue":"8","key":"e_1_2_9_28_1","first-page":"496","article-title":"Urinary Retention in Adults: Evaluation and Initial Management","volume":"98","author":"Serlin D. C.","year":"2018","journal-title":"American Family Physician"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12148"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12475"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2022.100674"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290685"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12417"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S411841"}],"container-title":["LUTS: Lower Urinary Tract Symptoms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/luts.12535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T01:28:20Z","timestamp":1732670900000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/luts.12535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/luts.12535"],"URL":"https:\/\/doi.org\/10.1111\/luts.12535","archive":["Portico"],"relation":{},"ISSN":["1757-5664","1757-5672"],"issn-type":[{"value":"1757-5664","type":"print"},{"value":"1757-5672","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"2024-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12535"}}